Back to Search
EDWIN PASCAL ALYEA, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1215974993IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
74343(MA)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
DUKE UNIVERSITY SCHOOL OF MEDICINE
Class of 1989
Research & Publications (20)
Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect.
PMID 18503989·Best Pract Res Clin Haematol·2008
6-review
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
PMID 18640576·Biol Blood Marrow Transplant·2008
3-trial
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
PMID 17067911·Biol Blood Marrow Transplant·2006
4-observational
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
PMID 15459007·Blood·2005
3-trial
CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.
PMID 15133487·Bone Marrow Transplant·2004
3-trial
Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.
PMID 11939603·Biol Blood Marrow Transplant·2002
8-other
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.
PMID 12359762·Cancer Res·2002
8-other
T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
PMID 11493435·Blood·2001
3-trial
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
PMID 14647268·Bone Marrow Transplant·2003
4-observational
Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.
PMID 19203731·Biol Blood Marrow Transplant·2009
8-other
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
PMID 19539216·Biol Blood Marrow Transplant·2009
3-trial
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
PMID 19168788·Blood·2009
8-other
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
PMID 19159415·Transfusion·2009
3-trial
Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation.
PMID 19667266·J Clin Oncol·2009
5-case
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
PMID 18974373·Blood·2009
3-trial
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
PMID 19556425·Blood·2009
3-trial
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
PMID 18776081·Blood·2008
8-other
Imaging of complications of hematopoietic stem cell transplantation.
PMID 18619387·Radiol Clin North Am·2008
6-review
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
PMID 19001324·J Clin Oncol·2008
4-observational
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
PMID 18342784·Biol Blood Marrow Transplant·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, DANA FARBER INSTITUTE
BOSTON, MA 02115 - Phone
- (617) 632-3903
Quick Facts
- NPI
- 1215974993
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile